Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Molecular Partners AG
Total Liabilities
Molecular Partners AG
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Total Liabilities
CHf21.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Total Liabilities
$343.4m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Total Liabilities
CHf154.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-9%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Total Liabilities
CHf1.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Total Liabilities
CHf33.3m
|
CAGR 3-Years
30%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Total Liabilities
CHf15.4m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Total Liabilities?
Total Liabilities
21.8m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Total Liabilities amounts to 21.8m CHF.
What is Molecular Partners AG's Total Liabilities growth rate?
Total Liabilities CAGR 5Y
-23%
Over the last year, the Total Liabilities growth was 29%. The average annual Total Liabilities growth rates for Molecular Partners AG have been -7% over the past three years , -23% over the past five years .
